GL1X · GenesisL1 explorer

Research workbench

Insights into hunter syndrome from the structure of iduronate-2- sulfatase

Analyse Insights into hunter syndrome from the structure of iduronate-2- sulfatase in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
5FQL
Type
protein
Length
507 residues
Chains
1
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Iduronate-2-sulfatase
EC
3.1.6.13
UniProt
P22304
Ligands
NAG, FUC, CA, CL
Pockets
4 · best druggability 0.58

Structure

x-ray diffraction · 1 distinct chain · 30% helix, 21% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
AIduronate-2-sulfatase (EC 3.1.6.13)protein50730% helix, 21% strandP22304

Ligands and binding sites

  • NAG · 2-acetamido-2-deoxy-beta-D-glucopyranose · sugar · 12 copies · chains A
  • FUC · alpha-L-fucopyranose · sugar · 3 copies · chains A
  • CA · Calcium ion · metal · chains A
  • CL · Chloride ion · ion · 3 copies · chains A

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

4 pockets found on a 1 Å grid, 2 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
13100.580.7729empty
23110.550.7538empty
31020.440.7819empty
41180.420.7622CL

Modifications

Observed in the structure: 7 glycan, 2 disulfide, 1 modified (N-glycosylation, disulfide, nonstandard).

Compared structures

  • 5FQL · Insights into Hunter syndrome from the structure of iduronate-2- sulfatase · the same entry in another collection · chain A against A, TM-score 1.00
  • P22304 · AlphaFold monomer V2.0 prediction for iduronate 2-sulfatase (P22304) · a predicted model of the same protein · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.